iperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystem

Autor(es)

Quijia, Christian Rafael ^[1] ; Chorilli, Marlus ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Phytotherapy Research; v. 36, n. 1 SEP 2021.
• Citações Web of Science: 1

Resumo

Piperine (PIP) is an alkaloid found primarily in Piper longum, and this natural compound has been shown to exert effects on proliferation and survival against various types of cancer. In particular, PIP has potent inhibitory effects on breast cancer (BC), the most prevalent type of cancer in women worldwide. PIP targets numerous signaling pathways associated with the therapy of BC cells through the following mechanisms: (a) induction of arrest of the cell cycle and apoptosis; (b) alteration of the signaling protein expression; (c) reduction in transcription factors; and (d) inhibition of tumor growth. BC cells have the ability to resist conventional drugs, so one of the strategies is the combination of PIP with other phytochemicals such as paclitaxel, thymoquinone, hesperidin, bee venom, tamoxifen, mitoxantrone, piperlongumin, and curcumin. Nanotechnology-based drug encapsulation systems are currently used to enhance the release of PIP. This includes polymer nanoparticles, carbon nanotubes, and liposomes. In the present review, the chemistry and bioavailability of PIP, its molecular targets in BC, and nanotechnological strategies are discussed. Future research directions are also discussed to further understand this promising natural product. (AU)

• Processo FAPESP: 18/21119-0 - Avaliação do potencial da piperina encapsulada em metal-organic frameworks revestidos com membranas de macrófagos no tratamento do Câncer de Mama
• Beneficiário: Christian Rafael Quijia Quezada
• Modalidade de apoio: Bolsas no Brasil - Doutorado